U. S. Department of health and human services (hhs), the national institutes of health (nih) and the centers for disease control and prevention (cdc) small business innovative research (sbir) program



Download 0.69 Mb.
Page1/27
Date19.10.2016
Size0.69 Mb.
  1   2   3   4   5   6   7   8   9   ...   27

U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES (HHS), THE NATIONAL INSTITUTES OF HEALTH (NIH) AND THE CENTERS FOR DISEASE CONTROL AND PREVENTION (CDC) SMALL BUSINESS INNOVATIVE RESEARCH (SBIR) PROGRAM

PROGRAM SOLICITATION PHS 2014-1

Closing Date: November 13, 2013, 4:30PM Eastern Time

Participating HHS Components:

The National Institutes of Health (NIH)

The Centers for Disease Control and Prevention (CDC)



IMPORTANT

Deadline for Receipt: Proposals must be submitted by November 13, 2013, 4:30PM Eastern Time

Solicitation Changes:

As a result of program reauthorization, the solicitation has been EXTENSIVELY rewritten and follows the changes of the SBIR/STTR reauthorization. Please read the entire solicitation carefully prior to submitting your proposal.

Please go to http://www.sbir.gov/about/sbir-policy-directive to read the SBIR/STTR Policy Directive issued by the Small Business Administration.



Table of Contents


cccxxviINTRODUCTION 3

cccxxviiPROGRAM DESCRIPTION 5

cccxxvii.1Objectives 5

cccxxvii.2Three Phase Program 5

cccxxvii.3Grant Opportunity - Phase IIB Competing Renewal Awards (INFORMATION ONLY) 6

cccxxvii.4Awarding Components 6

cccxxviiiDEFINITIONS 8

cccxxviii.1General Definitions 8



cccxxixWas not majority-owned by multiple venture capital operating companies (VCOCs), hedge funds, or private equity firms on the date on which it submitted an application in response to a solicitation under the SBIR program; and 8

cccxxxIs majority-owned by multiple venture capital operating companies, hedge funds, or private equity firms on the date of the SBIR award. 8

cccxxxiOwnership and control. 10

cccxxxiiBe a concern which is more than 50% directly owned and controlled by one or more individuals (who are citizens or permanent resident aliens of the United States), other business concerns (each of which is more than 50% directly owned and controlled by individuals who are citizens or permanent resident aliens of the United States), or any combination of these; OR 10

cccxxxiiiBe a concern which is more than 50% owned by multiple venture capital operating companies, hedge funds, private equity firms, or any combination of these. No single venture capital operating company, hedge fund, or private equity firm may own more than 50% of the concern; OR 10

cccxxxivBe a joint venture in which each entity to the joint venture must meet the requirements set forth in paragraph (a)(1)(i) or (a)(1)(ii) of this section. A joint venture that includes one or more concerns that meet the requirements of paragraph (ii) of this section must comply with § 121.705(b) concerning registration and proposal requirements 10

cccxxxvIf an Employee Stock Ownership Plan owns all or part of the concern, SBA considers each stock trustee and plan member to be an owner. 10

cccxxxviIf a trust owns all or part of the concern, SBA considers each trustee and trust beneficiary to be an owner. 10

cccxxxviiSize. An SBIR awardee, together with its affiliates, will not have more than 500 employees. 10

cccxxxvii.1Definitions (Relating to R&D) 11



cccxxxviiiPatient-Oriented Research. Research conducted with human subjects (or on material of human origin such as tissues, specimens, and cognitive phenomena) for which an investigator (or colleague) directly interacts with human subjects. Excluded from this definition are in vitro studies that utilize human tissues that cannot be linked to a living individual. Patient-oriented research includes: 11

cccxxxixmechanisms of human disease, 11

cccxltherapeutic interventions, 11

cccxliclinical studies, or 11

cccxliidevelopment of new technologies. 11

cccxliiiEpidemiologic and Behavioral Studies. 11

cccxlivOutcomes Research and Health Services Research. 11

cccxlvUnit process level technologies that create or improve manufacturing processes including: 13

cccxlviMachine level technologies that create or improve manufacturing equipment, including: 13

cccxlviiSystems level technologies for innovation in the manufacturing enterprise, including: 13

cccxlviiiEnvironment or societal level technologies that improve workforce abilities, productivity, and manufacturing competitiveness, including: 13

cccxlixresearch on regular and special education instructional strategies, or 15

ccclresearch on the effectiveness of or the comparison among instructional techniques, curricula, or classroom management methods. 15

cccliResearch involving the use of educational tests (cognitive, diagnostic, aptitude, achievement), survey procedures, interview procedures or observation of public behavior, unless: 15

cccliiany disclosure of the human subjects' responses outside the research could reasonably place the subjects at risk of criminal or civil liability or be damaging to the subjects' financial standing, employability, or reputation. 15

cccliiiResearch involving the use of educational tests (cognitive, diagnostic, aptitude, achievement), survey procedures, interview procedures, or observation of public behavior that is not exempt under paragraph (b)(2) of this section, if: 15

ccclivfederal statute(s) require(s) without exception that the confidentiality of the personally identifiable information will be maintained throughout the research and thereafter. 15

ccclvResearch involving the collection or study of existing data, documents, records, pathological specimens, or diagnostic specimens, if these sources are publicly available or if the information is recorded by the investigator in such a manner that subjects cannot be identified, directly or through identifiers linked to the subjects. 15

ccclviResearch and demonstration projects which are conducted by or subject to the approval of department or agency heads, and which are designed to study, evaluate, or otherwise examine: 15

ccclviiprocedures for obtaining benefits or services under those programs; 15

ccclviii possible changes in or alternatives to those programs or procedures; or 15

ccclixpossible changes in methods or levels of payment for benefits or services under those programs. 15

ccclxTaste and food quality evaluation and consumer acceptance studies, 15

ccclxiif a food is consumed that contains a food ingredient at or below the level and for a use found to be safe, or agricultural chemical or environmental contaminant at or below the level found to be safe, by the Food and Drug Administration or approved by the Environmental Protection Agency or the Food Safety and Inspection Service of the U.S. Department of Agriculture. 15

ccclxiiPROPOSAL FUNDAMENTALS 17

ccclxii.1Introduction 17

ccclxii.2Offeror Eligibility and Performance Requirements 17

ccclxii.3Multiple Principal Investigators 17

ccclxii.4Joint Ventures 18

ccclxii.5Majority Ownership in Part by Multiple Venture Capital, Hedge Fund, and Private Equity Firms (NIH COMPONENTS ONLY) 18



ccclxiiiAnswer the 3 questions and check the certification boxes. 18

ccclxivThe authorized business official must sign the certification. 18

ccclxvThe signed SBIR Application VCOC Certification must be submitted as part of the Pricing Proposal. 18

ccclxv.1Majority Ownership in Part by Multiple Venture Capital, Hedge Fund, and Private Equity Firms (CDC COMPONENTS ONLY) 18

ccclxv.2Conflicts of Interest 18

ccclxv.3Market Research. 19

ccclxv.4OMB Clearance 19

ccclxv.5Research Involving Human Subjects 19

ccclxv.6Care of Live Vertebrate Animals 20

ccclxv.7Research Involving Recombinant DNA Molecules 20

ccclxv.8Debriefing 21

ccclxv.9Phase I Award and (FAST TRACK NIH ONLY) Information 21

ccclxv.10Phase II/FAST TRACK Award Information 21

ccclxv.11Registrations and Certifications 21

ccclxv.12Promotional Materials 22

ccclxv.13Prior, Current, or Pending Support of Similar Proposals or Awards 22

ccclxv.14Fraud and False Statements 23

ccclxv.15State and Other Assistance Available 23



ccclxvimaking better technical decisions concerning such projects; 23

ccclxviisolving technical problems which arise during the conduct of such projects; 23

ccclxviiiminimizing technical risks associated with such projects; and 23

ccclxixdeveloping and commercializing new commercial products and processes resulting from such projects. 23

ccclxix.1Payment 23

ccclxix.2Proprietary Information 24

ccclxix.3Identification and Marking of SBIR Technical Data in Proposals 24



ccclxxCONTRACT REQUIREMENTS 25

ccclxx.1Other Contract Requirements 25

ccclxx.2Special Contract Requirements 26

ccclxx.3Copyrights 27

ccclxx.4Patents 27

ccclxx.5Technical Data Rights 27



ccclxxiSBIR agencies must protect from disclosure and non-governmental use all SBIR technical data developed from work performed under an SBIR funding agreement for a period of not less than four years from delivery of the last deliverable under that agreement (either Phase I, Phase II, or Federally-funded SBIR Phase III) unless, subject to paragraph (b) (3) of this section, the agency obtains permission to disclose such SBIR technical data from the awardee or SBIR applicant. Agencies are released from obligation to protect SBIR data upon expiration of the protection period except that any such data that is also protected and referenced under a subsequent SBIR award must remain protected through the protection period of that subsequent SBIR award. For example, if a Phase III award is issued within or after the Phase II data rights protection period and the Phase III award refers to and protects data developed and protected under the Phase II award, then that data must continue to be protected through the Phase III protection period. Agencies have discretion to adopt a protection period longer than four years. The Government retains a royalty-free license for Government use of any technical data delivered under an SBIR award, whether patented or not. This section does not apply to program evaluation. 27

ccclxxiiSBIR technical data rights apply to all SBIR awards, including subcontracts to such awards, that fall within the statutory definition of Phase I, II, or III of the SBIR Program, as described in section 4 of the SBIR Policy Directive. The scope and extent of the SBIR technical data rights applicable to Federally-funded Phase III awards is identical to the SBIR data rights applicable to Phases I and II SBIR awards. The data rights protection period lapses only: 27

ccclxxiiiBy agreement between the awardee and the agency. 28

ccclxxiii.1Invention Reporting 28



ccclxxivMETHOD OF EVALUATION 29

ccclxxiv.1Evaluation Process 29

ccclxxiv.2Phase I Technical Evaluation Criteria 29

ccclxxvThe qualifications of the proposed PDs/PIs, is the leadership approach, including the designated roles and responsibilities, governance, and organizational structure, consistent with and justified by the aims of the project and expertise of each of the PDs/PIs? 30

ccclxxviThe potential of the proposed research for technological innovation. 30

ccclxxviiThe potential of the proposed research for commercial application. The commercial potential of a proposal will be assessed using the following criteria: 30

ccclxxviiiThe adequacy and suitability of the facilities and research environment. 30

ccclxxviii.1FAST TRACK (NIH ONLY)/Phase II Technical Evaluation Criteria Evaluation Criteria 31



ccclxxixThe potential of the proposed research for commercialization, as documented in the offeror’s Commercialization Plan and evidenced by (a) the offeror’s record of successfully commercializing its prior SBIR/STTR or other research projects (b) commitments of additional investment during Phase I and Phase III from private sector or other non-SBIR funding sources, and (c) any other indicators of commercial potential for the proposed research. 31

ccclxxxThe qualifications of the proposed PDs/PIs, supporting staff and consultants. 31

ccclxxxiThe adequacy and suitability of the facilities and research environment. 31

ccclxxxi.1Award Decisions 31



ccclxxxiiAreas of high program relevance; 31

ccclxxxiiiProgram balance (i.e., balance among areas of research); and 31

ccclxxxivAvailability of funds. 31

ccclxxxvCost/Price 31

ccclxxxviPROPOSAL SUBMISSION 32

ccclxxxvi.1Limitation on the Length of the Technical Proposal. 32

ccclxxxvi.2Submission, Modifications, Revision, and Withdrawal of Proposals 32

ccclxxxviiThere is acceptable evidence to establish that it was received at the Government installation designated for receipt of proposals and was under the Government’s control prior to the time set for receipt of proposals; or 32

ccclxxxviiiIt was the only proposal received under the HHS Component Topic. 32

ccclxxxixAcceptable evidence to establish the time of receipt at the Government installation includes the time/date stamp of that installation on the proposal wrapper, other documentary evidence of receipt maintained by the installation, or oral testimony or statements of Government personnel. 32

cccxcIf an emergency or unanticipated event interrupts normal Government processes so that proposals cannot be received at the Government office designated for receipt of proposals by the exact time specified in the solicitation, and urgent Government requirements preclude amendment of the solicitation closing date, the time specified for receipt of proposals will be deemed to be extended to the same time of day specified in the solicitation on the first work day on which normal Government processes resume. 32

cccxciProposals may be withdrawn by written notice at any time before award. One copy of withdrawn proposals should be retained in the contract file (see 4.803(a) (10)). Extra copies of the withdrawn proposals may be destroyed or returned to the offeror at the offerors request. Extremely bulky proposals must only be returned at the offeror’s request and expense. 32

cccxciiThe contracting officer must promptly notify any offeror if its proposal, modification, or revision was received late, and must inform the offeror whether its proposal will be considered, unless contract award is imminent and the notice prescribed in 15.503(b) would suffice. 33

cccxciiiLate proposals and modifications that are not considered must be held unopened, unless opened for identification, until after award and then retained with other unsuccessful proposals. 33

cccxcivIf available, the following must be included in the contracting office files for each late proposal, modification, revision, or withdrawal: 33

cccxcvA statement regarding whether the proposal was considered for award, with supporting rationale. 33

cccxcviThe envelope, wrapper, or other evidence of date of receipt. 33

cccxcvi.1How To Submit Proposals 33



cccxcviiPROPOSAL PREPARATION AND INSTRUCTIONS 34

cccxcvii.1Introduction 34

cccxcvii.2Phase I Proposal Instructions 34

cccxcvii.3Fast Track Proposal Instructions 35



cccxcviiiIdentification and Significance of the Problem or Opportunity. Provide a clear statement of the specific technical problem or opportunity addressed. 36

cccxcixTechnical Objectives. State the specific objectives of the Phase I effort, including the technical questions it will try to answer to determine the feasibility of the proposed approach. 36

cdWork Plan. Provide an explicit, detailed plan for the Phase I R&D to be carried out, including the experimental design, procedures, and protocols to be used. Address how the objectives will be met and the questions stated in Item b above. Discuss in detail the methods to be used to achieve each objective or task. The plan should indicate what is planned, how, when, and where the work will be carried out, a schedule of major events, the final product to be delivered, and the completion date of the effort. The Phase I effort should determine the technical feasibility of the proposed concept. 36

cdiRelated Research or R&D. Describe significant research activities directly related to the proposed effort, including any conducted by the Project Director/Principal Investigator (PD/PI), the proposing firm, consultants, or others. Describe how these activities interface with the proposed project and discuss any planned coordination with outside sources. The PD/PI must persuade reviewers of his or her awareness of recent significant research or R&D conducted by others in the same scientific field. 37

cdiiRelationship with Future R&D. 37

cdiiiState the anticipated results of the proposed approach, assuming project success. 37

cdivDiscuss the significance of the Phase I effort in providing a foundation for the Phase II R/R&D effort. 37

cdvPotential Commercial Applications. Describe why the proposed project is deemed to have potential commercial applications (for use by the Federal Government and/or private sector markets.) Describe the market as it currently exists and how your product may enter and compete in this market. Include the potential barriers to market entry and how you expect to overcome them. 37

cdviSenior/Key Personnel and Bibliography of Directly Related Work. Identify senior/key personnel, including their directly related education, experience, and bibliographic information. Where resumes are extensive, focus on summaries of the most relevant experience or publications. Provide dates and places of employment and some information about the nature of each position or professional experience. Resumes must identify the current or most recent position. 37

cdviiSubcontractors/Consultants. Involvement of a university or other subcontractors or consultants in the project may be appropriate and is permitted. If such involvement is intended, it should be described in detail and identified in the cost proposal. In addition, supported by appropriate letters from each individual confirming his/her role in the project must be included. Small business concerns must perform a minimum of two-thirds for Phase I of the research and/or analytical effort (i.e., total contract price less profit/fee) conducted under the resulting contract. The Contracting Officer must approve deviations from this requirement in writing after consultation with the agency SBIR Program Manager/Coordinator. 37

cdviiiFacilities and Equipment. Indicate where the proposed research will be conducted. One of the performance sites must be the offeror organization. Describe the facilities* to be used; identify the location; and briefly indicate their capacities, pertinent capabilities, relative proximity, and extent of availability to the project. Include clinical, computer, and office facilities of the offeror and those of any other performance sites to be used in the project. 37

cdixNIH FAST TRACK Only. Anticipated Results of the Phase I Effort 38

cdxResearch Plan for Phase II (FAST TRACK) Research Plan 38

cdxiPersonnel - List by name, title, department and organization, the extent of commitment to this Phase II effort, and detail each person’s qualifications and role in the project. Provide resumes for all key staff members, describing directly related education, experience, and relevant publications. Describe in detail any involvement of subcontractors or consultants, and provide resumes for all key subcontractor staff. Also, include letters of commitment with proposed consultants confirming the extent of involvement and hourly/daily rate. 38

cdxiiResources - List/describe all equipment, facilities and other resources available for this project, including the offeror’s clinical, computer and office facilities/equipment at any other performance site that will be involved in this project. Briefly state their capacities, relative proximity and extent of availability to this effort. (Any equipment specifically proposed as a cost to the contract must be justified in this section as well as detailed in the budget. Equipment and products purchased with Government funds shall be American-made, to the extent possible. Title to the equipment will vest in the Government.) 38

cdxiiiOther considerations - Provide a brief narrative of any unique arrangements, safety procedures in place, animal welfare issues, human subjects, etc. Note: If the research plan includes the use of human subjects or animals, refer to paragraphs Sections 4.10 and 4.11 of this solicitation for further guidance. 38

cdxivMultiple PD/PI Leadership Plan. For proposals designating multiple PDs/PIs, a leadership plan must be included. A rationale for choosing a multiple PD/PI approach should be described. The governance and organizational structure of the leadership team and the research project should be described, including communication plans, process for making decisions on scientific direction, and procedures for resolving conflicts. The roles and administrative, technical, and scientific responsibilities for the project or program should be delineated for the PDs/PIs and other collaborators. 38

cdxvIf budget allocation is planned, the distribution of resources to specific components of the project or the individual PDs/PIs should be delineated in the Leadership Plan. In the event of an award, the requested allocations may be reflected in Contract Award. 38

cdxviResource Sharing Plan(s). NIH considers the sharing of unique research resources developed through NIH-sponsored research an important means to enhance the value and further the advancement of the research. When resources have been developed with NIH funds and the associated research findings published or provided to NIH, it is important that they be made readily available for research purposes to qualified individuals within the scientific community. If the final data/resources are not amenable to sharing (for example, human subject concerns, the Small Business Act provisions, etc.), this must be explained in the proposal. See http://grants.nih.gov/grants/policy/data_sharing/data_sharing_faqs.htm. 38

cdxviiSharing Model Organisms: Regardless of the amount requested, all proposals where the development of model organisms is anticipated are expected to include a description of a specific plan for sharing and distributing unique model organisms or state appropriate reasons why such sharing is restricted or not possible. See Sharing Model Organisms Policy, and NIH Guide NOT-OD-04-042. 39

cdxviiiGenome Wide Association Studies (GWAS): Regardless of the amount requested, offerors seeking funding for a genome-wide association study are expected to provide a plan for submission of GWAS data to the NIH-designated GWAS data repository, or an appropriate explanation why submission to the repository is not possible. GWAS is defined as any study of genetic variation across the entire genome that is designed to identify genetic associations with observable traits (such as blood pressure or weight) or the presence or absence of a disease or condition. For further information see Policy for Sharing of Data Obtained in NIH Supported or Conducted Genome-Wide Association Studies, NIH Guide NOT-OD-07-088, and Genome-Wide Association Studies. 39

cdxixCommercialization Plan – Required for the Phase II portion of ALL Fast-Track proposals. The Phase II portion of Fast-Track proposals must include a succinct Commercialization Plan. The Commercialization Plan is limited to 12 pages. Be succinct. There is no requirement for offerors to use the maximum allowable pages allotted to the Commercialization Plan. 39

cdxxCompany. Give a brief description of your company including corporate objectives, core competencies, present size (annual sales level and number and types of employees), history of previous Federal and non-Federal funding, regulatory experience, and subsequent commercialization, and any current products/services that have significant sales. Include a short description of the origins of the company. Indicate your vision for the future, how you will grow/maintain a sustainable business entity, and how you will meet critical management functions as your company evolves from a small technology R&D business to a successful commercial entity. 39

cdxxiMarket, Customer, and Competition. Describe the market and/or market segments you are targeting and provide a brief profile of the potential customer. Tell what significant advantages your innovation will bring to the market, e.g., better performance, lower cost, faster, more efficient or effective, new capability. Explain the hurdles you will have to overcome in order to gain market/customer acceptance of your innovation. 39

cdxxiiDescribe any strategic alliances, partnerships, or licensing agreements you have in place to get FDA approval (if required) and to market and sell your product. 39

cdxxiiiBriefly describe your marketing and sales strategy. Give an overview of the current competitive landscape and any potential competitors over the next several years. (It is very important that you understand and know the competition.) 39

cdxxivIntellectual Property (IP) Protection. Describe how you are going to protect the IP that results from your innovation. Also note other actions you may consider taking that will constitute at least a temporal barrier to others aiming to provide a solution similar to yours. 39

cdxxvFinance Plan. Describe the necessary financing you will require, and when it will be required, as well as your plans to raise the requisite financing to launch your innovation into Phase III and begin the revenue stream. Plans for this financing stage may be demonstrated in one or more of the following ways: 40

cdxxviLetter of commitment of funding. 40

cdxxviiLetter of intent or evidence of negotiations to provide funding, should the Phase II project be successful and the market need still exist. 40

cdxxviiiLetter of support for the project and/or some in-kind commitment, e.g., to test or evaluate the innovation. 40

cdxxixSpecific steps you are going to take to secure Phase III funding. 40

cdxxxProduction and Marketing Plan. Describe how the production of your product/service will occur (e.g., in-house manufacturing, contract manufacturing). Describe the steps you will take to market and sell your product/service. For example, explain plans for licensing, internet sales, etc. 40

cdxxxiRevenue Stream. Explain how you plan to generate a revenue stream for your company should this project be a success. Examples of revenue stream generation include, but are not limited to, manufacture and direct sales, sales through value added resellers or other distributors, joint venture, licensing, service. Describe how your staffing will change to meet your revenue expectations. 40

cdxxxiiOfferors are encouraged to seek commitment(s) of funds and/or resources from an investor or partner organization for commercialization of the product(s) or service(s) resulting from the SBIR contract. 40

cdxxxiiiYour Phase III funding may be from any of a number of different sources including, but not limited to: SBIR firm itself; private investors or “angels”; venture capital firms; investment companies; joint ventures; R&D limited partnerships; strategic alliances; research contracts; sales of prototypes (built as part of this project); public offering; state finance programs; non SBIR-funded R&D or production commitments from a Federal agency with the intention that the results will be used by the United States government; or other industrial firms. 40

cdxxxivPrior, Current, or Pending Support of Similar Proposals or Awards. If a proposal submitted in response to this solicitation is substantially the same as another proposal that was funded, is now being funded, or is pending with another Federal Agency, or another or the same HHS Component, you must reveal this on the Proposal Cover Sheet and provide the following information: 40

cdxxxvDate of proposal submission or date of award. 40

cdxxxviTitle of proposal. 40

cdxxxviiName and title of principal investigator for each proposal submitted or award received. 40

cdxxxviiiTitle, number, and date of solicitation(s) under which the proposal was submitted, will be submitted, or under which award is expected or has been received. 40

cdxxxixIf award was received, state contract number. 40

cdxlSpecify the applicable topics for each SBIR/STTR proposal submitted or award received. 40

cdxl.1Human Subjects Research and Protection from Risk 41

cdxl.2Research Involving Prisoners as Subjects 46

cdxl.3Research Involving Human Fetal Tissue 47

cdxl.4Research Involving Live Vertebrate Animals 47

cdxliJustify the use of animals, the choice of species, and the numbers to be used. If animals are in short supply, costly, or to be used in large numbers, provide an additional rationale for their selection and numbers. 47

cdxliiProvide information on the veterinary care of the animals involved. 47

cdxliiiDescribe the procedures for ensuring that discomfort, distress, pain, and injury will be limited to that which is unavoidable in the conduct of scientifically sound research. Describe the use of analgesic, anesthetic, and tranquilizing drugs and/or comfortable restraining devices, where appropriate, to minimize discomfort, distress, pain, and injury. 47

cdxlivDescribe any method of euthanasia to be used and the reasons for its selection. State whether this method is consistent with the recommendations of the Panel on Euthanasia of the American Veterinary Medical Association. If not, present a justification for not following the recommendations. 47

cdxliv.1Content of the Pricing Proposal (Item Two). 48



cdxlvOfferors submitting proposals may include the amount of $5,000 for technical assistance as discussed and outlined in Section 4.20 of the solicitation. 49

cdxlv.1Proposal Checklists 49



cdxlviProposal Cover Sheet Appendix A (1 Original, 5 Copies) 49

cdxlviiTable of Contents 49

cdxlviiiAbstract of the Research Plan, (Appendix B) (1 Original, 10 Copies) 49

cdxlixContent of the Technical Element 49

cdlTable of Contents 49

cdliAbstract of the Research Plan, (Appendix B) (1 Original, 10 Copies) 49

cdliiContent as outlined in the Technical Element Description 49

cdliiiDraft Statement of Work (Appendix E) 49

cdliv Summary of Related Activities (Appendix F) 49

cdlvCheck that the cost adheres to the Component criteria specified and the price on the cover sheets matches the price in the Pricing proposal. 50

cdlviCheck that the Project Abstract and other content provided on the cover sheets contain NO proprietary information. 50

cdlviiMark proprietary information within the Technical Proposal as instructed in Section 4.23. 50

cdlviiiThat the header on each page of the technical proposal should contain the company name and topic number. 50

cdlixEnsure that if you have proposed for your research to include Human Subjects or Research on Animals that you have addressed the requirements outlined in the solicitation in the Technical proposal as necessary. 50

cdlxSUMMARY OF HHS COMPONENTS ANTICIPATED NUMBER OF AWARDS 51

cdlxiCONTRACTING OFFICERS AND ADDRESSES FOR DELIVERY OF CONTRACT PROPOSALS 53

National Institutes of Health (NIH) 53

National Cancer Institute (NCI) 53

National Center for Advancing Translational Sciences (NCATS) 53

National Heart, Lung, and Blood Institute (NHLBI) 54

National Institute on Aging (NIA) 54

National Institute on Alcohol Abuse and Alcoholism (NIAAA) 54

National Institute of Allergy and Infectious Diseases (NIAID) 55

National Institute on Drug Abuse (NIDA) 55

Centers for Disease Control and Prevention (CDC) 55

Center for Global Health (CGH) 56

National Center for Birth Defects and Developmental Disabilities (NCBDDD) 56

National Center for Chronic Disease Prevention and Health Promotion (NCCDPHP) 56

National Center for Emerging Zoonotic and Infectious Diseases (NCEZID) 57

National Center for HIV/AIDs, Viral Hepatitis, STD, and TB Prevention (NCHHSTP) 57

National Center for Immunization and Respiratory Diseases (NCIRD) 57

Office of Public Health Preparedness and Response (OPHPR) 57

cdlxiiSCIENTIFIC AND TECHNICAL INFORMATION SOURCES 59

cdlxiiiCOMPONENT INSTRUCTIONS AND TECHNICAL TOPIC DESCRIPTIONS 60

National Institutes of Health 60

National Cancer Institute (NCI) 60

cdlxivDevelopment of Novel Therapeutic Agents that Target Cancer Stem Cells 61

cdlxvreproducible and viable operation with simple and clear protocols; 65

cdlxviability to examine multiple aspects of cancer, such as tumor growth, angiogenesis, cell proliferation and cell death, migration, and/or invasion; and 65

cdlxviicompatibility with high content screening platforms that include multiple molecular read-outs, such as genomic, proteomic, metabolomic, or epigenomic analyses. 65

cdlxviiiverification of the specific phospho-sites; 69

cdlxixquantification of site-specific phospho-residues. 69

cdlxxAllow the efficient import of additional relevant data from diverse sources such as physiological data, survey results, field-collected information, and mobile devices. 76

cdlxxiCompile data at multiple geo-located scales such as point addresses, buffers, and administrative boundaries including but not limited to census elements. 76

cdlxxiiAllow the compilation of data into matrices easily transferable into relevant analytical software packages, including statistical and graphics packages. 76

cdlxxiiiSupply scripts or protocols to allow visualization of the correlation structure among collated variables. 76

cdlxxivDemonstrably allow the recreation of existing metrics related to the food and physical activity environments. 76

cdlxxvContain plans for extending these tools into products useful for specific clients such as those in government and public sectors, foundations, and other non-governmental organizations. 76

cdlxxviRecreate existing indices, replicate their estimates, and then modify them with new data elements or new weighting schemes. 77

National Center for Advancing Translational Sciences (NCATS) 78



326 Development of biomarkers for rare diseases as endpoints for clinical trial measurements 78

cdlxxviiDevelopment of Neurocognitive Pediatric Tools for Measuring and Analyzing Clinical Study Endpoints in Rare Neurocognitive Disorders 79

cdlxxviiiExploring the Potential of CRISPR/CAS Genome-editing Tools 80

cdlxxixDroplet Detection System 81

National Heart, Lung, and Blood Institute (NHLBI) 83



326Passive MRI Cardiovascular Guidewire 84

National Institute on Aging (NIA) 92

National Institute on Alcohol Abuse and Alcoholism (NIAAA) 95

National Institute of Allergy and Infectious Diseases (NIAID) 96



326Biomedical Methods To Quantify Adherence To Prevention Clinical Trial Study Products and Strategies 96

cdlxxxSimple, Inexpensive Assay for Five Common HIV Resistance Mutations 97

cdlxxxiCapreomycin: Formulation for Oral Delivery 98

cdlxxxiiAdjuvant Development 99

National Institute on Drug Abuse (NIDA) 100



326Web Resource System for Prescription Drug Providers, Researchers and Users: The Prescription Drug Abuse Policy System (PDAPS) 100

cdlxxxiiiAffordable Care Act (ACA) Web Platform to Integrate Behavioral Health & Prevention with Primary Care 112

Centers for Disease Control and Prevention (CDC) 115

Center for Global Health (CGH) 115

326Development of Novel Malaria Parasite Metabolite-based Non-invasive Diagnostic Biosensor 115

National Center on Birth Defects and Developmental Disabilities (NCBDDD) 116



326Developing Rapid Test for the Diagnosis of Sickle Cell Disease 116

cdlxxxivDevelopment of Rapid, Point-of-care Tests for Cytomegalovirus (CMV) 117

cdlxxxvTo develop a sensitive and specific device for a rapid, point-of-care test to detect CMV DNA or proteins in urine or saliva. The device should be easy to operate and maintain. Additionally, the results should be easy to interpret with minimal training. The device will have potential for use in screening newborns for congenital CMV infection. 118

cdlxxxviIgG screening or (2) CMV DNA or protein screening 118

cdlxxxviiNutrition Support for Group Homes Serving Individuals with Intellectual Disabilities 119

National Center for Chronic Disease Prevention and Health Promotion (NCCDPHP) 120



326Promoting Regular Physical Activity for Older Adults through “Wayfinding” Technology 120

cdlxxxviiiDevelopment of Pills or Tablets to Expedite Water Fluoridation 121

cdlxxxixApplication for Improving Embryo Transfer Practices at Fertility Clinics 122

National Center for Emerging Zoonotic and Infectious Diseases (NCEZID) 123



326Distinguishing Infection, Colonization, and Recurrence in Patients with Clostridium difficile 123

cdxcPerform the quantitative serologic assay on 30-paired acute and convalescent sera from patients with clinical and laboratory documentation of incident (i.e. non-recurrent) CDI to set cutoffs for quantitative levels. 124

cdxciDevelop an assay to interrogate C. difficile toxin A and/or B antibodies from newly proliferated, circulating antibody-secreting cells in the blood (e.g. circulating plasmablasts). 124

cdxciiPerform interrogation of circulating antibody-secreting cells and trace quantitative IgG/IgA levels specific for C. difficile toxin A and/or B on serially collected samples, beginning on the day of CDI diagnosis and between daily and weekly until 12 weeks post infection, from at least 10 individual patients with acute, incident (i.e. non-recurrent) CDI, to trace the humeral immune responses of acute CDI. 124

cdxciiiDevelopment of Reagents for Diagnosis of Fungal Infections in Formalin-fixed Paraffinized (FFPE) Tissue Blocks 124

cdxcivRapid Detection of Endemic Fungal Infections in the United States 125

cdxcvDevelopment of Anti-Japanese Encephalitis Virus Human Monoclonal Antibodies Using Humanized Rodent Models 126

cdxcviVaccinate animals, isolate activated B cells to JEV antigen, and immortalize or engineer cell lines capable of constitutively expressing anti-JEV MAbs. 127

cdxcviiFormulation of Nootkatone in Soaps and Lotions for Lyme Disease Prevention 127

National Center for HIV/AIDs, Viral Hepatitis, STD, and TB Prevention (NCHHSTP) 127



326Development of a Rapid Test for detection hepatitis C core antigen in clinical samples. 128

cdxcviiiDevelopment of a Laboratory Test for Detection of Serum Biomarkers Associated with Hepatocellular Carcinoma 129

cdxcixText my EOB: The Innovative Delivery of Confidential Medical Information 130

dDevelopment of a Mobile Application for Homeless Youth and Providers 131

diActivity: Develop and input content for youth, particularly content relevant to homeless youth, including critical HIV/STI/pregnancy prevention information and nearby health care and social services; and for providers including up-to-date information on providing care to youth, both homeless and LGBT youth; and integrating public health into practice and making referrals etc. 132

diiActivity: Explore ways to link Module I and II so that resources can remain up to date and service providers can best serve youth. Develop a way for each population (youth or providers) to see only their respective module when using the app. 132

diiiActivity: Consider piloting the initial versions of the app with members of the target audience in a nearby area to gage their experience with services, as well as their impressions of the app, to improve the design. 132

divDeliverable (pilot mobile app): Develop a proof of concept mobile app for homeless youth, homeless LGBT youth and providers for use on a variety of mobile devices and platforms (smart phones; tablets; computers; gaming systems etc.) Equip the mobile app with the ability for youth to track, record and rate use of services and their locations to help healthcare settings reach homeless youth with reminders, and/or keep track of them in the system, and improve their service offerings. Consider a youth “check-in” feature to gauge mobility patterns to better provide services/mobile services. 132

dvLeveraging Technology to Prevent STIs Using High-Intensity Behavioral Counseling 132

dviAssessing the Feasibility of e-measure Adoption in an EHR Environment 133

National Center for Immunization and Respiratory Diseases (NCIRD) 134



326Thermostable Dry Vaccine Formulation for Microneedle Administration 134

dviiDevelopment of Anti-diphtheria Antibodies for Use in Humans 135

Office of Public Health Preparedness and Response (OPHPR) 136



326“Plug and Play” Global Health Security Initiative (GHSI) Response Tool 136

dviiiMonthly progress report meetings to monitor progress or work issues and problems. 137

dixImproved Rapid Antimicrobial Susceptibility Testing from Primary Specimens 137

dxAPPENDICIES 139

APPENDIX A — PROPOSAL COVER SHEET - USE FOR PHASE I AND FAST-TRACK PROPOSALS 139

APPENDIX B — ABSTRACT OF RESEARCH PLAN - USE FOR PHASE I, PHASE II, AND FAST-TRACK PROPOSALS 139

APPENDIX C — PRICING PROPOSAL - USE FOR PHASE I, PHASE II AND FAST-TRACK PROPOSALS 139

APPENDIX D — PHASE II TECHNICAL PROPOSAL COVER SHEET - USE FOR PHASE II AND FAST-TRACK PROPOSALS 139

APPENDIX E — STATEMENT OF WORK SAMPLE FORMAT - USE FOR PHASE II AND FAST-TRACK PROPOSALS 139

APPENDIX F — SUMMARY OF RELATED ACTIVITIES - USE FOR PHASE II AND FAST- TRACK PROPOSALS 139

APPENDIX G — PROPOSAL SUMMARY AND DATA RECORD - USE FOR PHASE II AND FAST-TRACK PROPOSALS 139






Download 0.69 Mb.

Share with your friends:
  1   2   3   4   5   6   7   8   9   ...   27




The database is protected by copyright ©ininet.org 2020
send message

    Main page